SELLAS Life Sciences (SLS) Net Cash Flow (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Net Cash Flow data on file, last reported at $35.4 million in Q1 2026.

• On a quarterly basis, Net Cash Flow rose 143.61% year-over-year to $35.4 million in Q1 2026; TTM through Mar 2026 was $78.7 million, a 688.77% increase from a year earlier, with the FY2025 full-year figure at $57.9 million, up 409.83% from the prior year.
• Net Cash Flow for Q1 2026 stood at $35.4 million, up from $27.5 million in the prior quarter.
• Over the last five years, Net Cash Flow for SLS reached as high as $35.4 million in Q1 2026 and fell as low as -$9.8 million in Q3 2023.
• Historically, Net Cash Flow has averaged $5.5 million across 5 years, with a median of -$1.4 million in 2023.
• Across the five-year window, Net Cash Flow soared 814.81% in 2022 and slumped 396.53% in 2024, its largest moves.
• Year by year, Net Cash Flow stood at -$4.2 million in 2022, then soared by 65.92% to -$1.4 million in 2023, then tumbled by 396.53% to -$7.1 million in 2024, then soared by 484.35% to $27.5 million in 2025, then advanced by 28.72% to $35.4 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $35.4 million in Q1 2026, $27.5 million in Q4 2025, and $19.0 million in Q3 2025.